VOR · Vor Biopharma
Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Market Cap
1.138B
52 Wk Range
$6.69 - $26.00
Previous Close
$18.52
Open
$18.14
Volume
1,552,050
Day Range
$17.99 - $19.93
Enterprise Value
658.4M
Cash
481.6M
Avg Qtr Burn
-32.75M
Insider Ownership
8.92%
Institutional Own.
90.54%
Qtr Updated
Sep 30th 2026
